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Abstract
Introduction: There is evidence of rising neurological deaths in the Western world. This study examines any 
changes during the 21st century to indicate whether the causes are primarily demographic or environmental.
Method: All data based upon WHO mortality rates per million (pm) for WHO mortality categories Nervous 
Disease Deaths (NDD) and Alzheimer and Other Dementias Deaths (AlzD) to calculate a Combined 
Neurological Mortality rate for people aged 55-74 Year Olds (lower than Western life-expectancy) and 
AGE-STANDARDISED-DEATH-RATES (ASDR) (pm) for both sexes. Over75’s neurological deaths and 
population numbers analyzed to determine if increased mortality mainly due to an ageing population. 
Results: 55-74Year Olds: NDD rates were higher than AlzD in every country. Combined rates rose 
substantially in ten countries, although Canadian and French rates fell. Total ASDR: NDD and AlzD 
increased substantially in all countries. Highest combined rates rose from 476 per million (pm) to 973pm 
in Finland, followed by America 336 pm to 592 pm and UK 205 pm to 553 pm. Notable increases in 
numbers of deaths of 55-74-year-olds, below Western life-expectancy olds, were Austria 77%, Germany 
52%, Sweden 48%, Finland 44%, America 39%, Japan 36% the UK 32% in just 16 years. Examples of 
major rises in Total neurological deaths was in Britain going from 24,601 to 103,550 and in America from 
174,708 to 436,43, whilst Over75’s neurological deaths substantially outstripped population increases.
Conclusions: Neurological death rates are accelerating at an unprecedented rate, challenging the 
Gompertzian hypothesis that these increases are primarily due demographics, strongly indicating multiple 
interactive environmental causes.
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INTRODUCTION
Whilst the incidence of cardiovascular, cancer and 
neurological disease are strongly age-related in most 
developed countries, cardiovascular and cancers 
mortality rates have continued to fall over the past 
25 years in every-one of the 21 Western Developed 
Countries (WDC) [1-3]. The reverse has been the case 
in regard to neurological disease-related mortality in 
spite of substantial increases in overall life expectancy 
[3,4-8]. This includes conditions such as Alzheimer’s 
Disease, Motor Neurone Disease and Parkinson’s Disease 
as well are the much rarer Multiple System Atrophy and 
Progressive Supra-nuclear Palsy [6-8], though in regard 
to Motor Neurone Disease some authorities stated that 
the increases were mainly due to better diagnosis [9]. 
However, a range of other studies have found statistical 
associations between various neurological conditions and 
occupations such as chemicals, engineering, electronics 
and wider environmental influences [4,6,10-17]. The 
inference being that the reported increases are strongly 
influenced by multiple interactive environmental factors, 
impacting on any under-lying genetic predispositions. 
Others have argued that the rises were mainly due to 
demographic changes and rises in longevity, postulating 
the Gompertzian hypothesis. This hypothesis states that 
as people are living longer, they are now able to develop 
age-related diseases that they were not old enough to 
develop previously and therefore the apparent rises are 
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an artefact [18,19]. However, the Gompertzian hypothesis 
has been challenged as it cannot account for the 
differences between the sexes and especially the big rises 
in early-onset-dementias, although there are under-lying 
genetics factors associated with early dementias [20-25]. 
Nonetheless, in the media health correspondents often 
reflect the Gompertzian view by inferring the reasons 
for neurological increases are demographic and are 
mainly due to rises in the elderly (75+years) population. 
However, this study pays special attention to people 
aged 55-74years is below current life expectancy in the 
developed world. Hence mortality in this age-band might 
be considered as premature deaths.
This study builds upon earlier work [26] and asks 
whether the earlier reported increases in neurological 
death rates are accelerating in the 21st century in the 
twenty-one Western-Developed-Countries (WDC) [27]. 
These countries are Australia, Austria, Belgium, Canada, 
Denmark, Finland, France, Germany, Greece, Ireland, 
Italy, Japan, Netherlands, New Zealand, Norway, Portugal 
Spain, Sweden, Switzerland, UK and the USA. 
There is one working null hypothesis, that there will be 
no substantial rise in neurological mortality for both 
55-74-year-olds and total all age neurological ASDR 
between 2000 and 2015.
METHODOLOGY
This study draws upon the separate WHO global 
neurological diagnostic categories of Nervous Disease 
Deaths (NDD), and, Alzheimer’s and Other Dementia 
Deaths (AlzD) [27], which together produces the 
Combined Neurological Mortality (CNM) rates per 
million (pm) and examines changes over the relatively 
short period of 2000 to 2015. In addition, WHO Age-
Standardised-Death-Rates (ASDR) are examined which 
are deaths across all age-bands, controlled for age, gender 
and population for NDD and AlzD mortalities producing 
the Combined Neurological Mortality (CNM) rate over 
the period [27].
Any substantial rises are defined by any increases that 
produce an Odds Ratio (O.R) of >1:1.20, equivalent to 
+20% in NDD, AlzD or CNM over the 15-year period. 
`Notable’ rises occur if an Odds Ratios reaches >1:1.30 
that is equivalent to a 30% increase.
We compare each of the 21 WDC neurological mortality 
rates for the year 2000 with the latest WHO date 
available, which for most WDC is 2015. Canada, France, 
New Zealand and Portugal had earlier index years, noted 
in the tables, whilst Austria, Netherlands and Sweden 
had data for 2016 but to maintain consistency across 
the majority of countries we use these nation’s 2015 
outcomes [27].
Neurological disease mortality is reported in two 
global WHO mortality categories [27], Nervous Disease 
Deaths (NDD), coded G00-G99, and Alzheimer’ and the 
Dementias Deaths (AlzD), coded F01, F03, G30-31. We 
compare WHO Age-Standardised-Death-Rates (ASDR), 
which are based upon world population to provide 
a standardised total death rate, thus controlling for 
population. The NDD and AlzD ASDR rates are combined 
to produce the Combined Neurological Mortality (CNM) 
rate. A key focus is upon mature adults, people aged 55-
74year of both sexes for NDD and AlzD categories. The 
55-74 rates are obtained by examining the numbers of 
NDD and AlzD deaths divided by the 55-74-year-old 
population of that country to produce mortality rates 
per million (pm) and summing the NDD and AlzD rates 
provides the Combined Neurological Mortality (CNM) 
rates. Each country is its own control by comparing their 
baseline with their index years, from which a series of 
ratios of change are calculated.
In order to compare between countries of markedly 
different population sizes, it is necessary to use death 
rates. To some extent this can mask the practice reality 
of the extent of any subsequent rises and how this might 
impact upon the neurological and community services. 
So, the Numbers of neurological deaths of people aged 
55-74 and total numbers of neurological deaths are also 
reported and compared with the changes in the numbers 
of the 55-74 and total populations in each country. 
Ratios of change are then determined over the period 
for both age bands from which population to Combined 
Neurological Mortality (CMN) odds ratios are calculated.
RESULTS 
55-74-Year-olds 
Table 1 is for the 55-74year olds data, ranked by highest 
CNM rates, which rose substantially (>20%) in eleven 
countries over the sixteen years 2000-2015.
The separate category of NDD were higher than AlzD in 
every country both in year 2000 and 2015. There were 
substantial rises in twelve countries for NDD and eleven 
countries for AlzD. 
There was notable (>30%) rises in CNM in Austria 
up 77%, Australia 34%, Denmark 33%, Finland 44%, 
Germany 52%, Japan 36%, Sweden 48%, UK 32% and 
USA 39% in the century.
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Country and % Change NDD 55-74 2000-2015 Alzh 55-74 2000-2015 CNM 55-74 2000-2015
Finland % change 394-642 63% 305-364 19% 699-1006 44%
USA % change 364-455 25% 147-255 73% 511-710 39%
UK % change 256-399 56% 164-254 55% 420-653 32%
Sweden % change 267-387 45% 157-239 52% 424-626 48%
Netherland % change 350-379 8% 116-223 92% 466-602 29%
Denmark % change 339-398 17% 115-204 77% 454-602 33%
Norway % change 365-390 7% 125-176 39% 490-566 16%
Belgium % change 377-383 2% 206-172 -17% # 583-555 -5% #
Switzerland % change 297-356 20% 141-180 28% 438-536 22%
Ireland % change 291-345 19% 174-176 1% 465-521 12%
Spain % change 299-329 10% 195-179 -8% # 494-508 3%
Australia %change 272-335 23% 105-171 63% 377-506 34%
Canada 2013 % change 376-318 -15 # 159-165 4% 535-483 -10% #
Germany % change 254-342 35%  60-136 127% 314-478 52%
New Zealand 2013 % change 279-314 13% 129-161 25% 408-475 16%
Italy % change 266-327 23% 186-133 -28% # 452-460 2%
Portugal % change 230-290 26% 144-142 -1 % # 374-432 16%
France % change 397-321 -19 % # 173-119 -31% # 570-440 -23% #
Austria % change 160-286 79% 74-129 74% 234-415 77%
Greece % change 213-279 31% 121-99 -18% # 334-378 13%
Japan % change 123-180 46% 28-26 -7 % # 151-206 36%
#  rate fell over the period.
Table 1: Nervous Disease Deaths (NDD) & Alzheimer & Other Dementia Deaths (Alz) are Combined Neurological Mortality (CNM) 55-74-year-
olds rates per million 2000-2015 % Change. Rankled by Highest CNM rates.
Conversely, French rates fell for both NDD and AlzD an 
overall 23% decline for CNM. Belgium and Canada CNM 
rates fell 5% and 10% respectively. Conversely, there 
were falls in AlzD in Greece, Italy, Japan and Portugal 
although their overall CNM rates had increased over the 
period. 
Total ASDR 
A perusal of Table 2 shows that All but three country’s 
NDD rates rose more than 25% over the period, nine 
by more than 50%, Canada was the only nation to have 
a small decline, 10% in their NDD rates. Every country, 
Country and % Change NDD ASDR 2000-2015 Alzh ASDR 2000-2015 CNM ASDR 2000-2015
Finland % change 165-492 198% 311-481 55% 476-973 104%
USA % change 187-281 50% 149-311 109% 336-592 76%
UK % change 109-205 88%  96-348 262% 205-553 170%
Netherland % change 110-190 73% 164-297 81% 274-487 78%
Sweden % change 101-175 73% 156-261 67% 257-436 70%
Ireland % change 130-186 43% 78-225 188% 208-411 98%
Switzerland % change 151-171 13% 142-239 68% 293-410 40%
Spain % change 132-188 42% 166-215 30% 298-403 35%
Denmark % change 122-173 42% 100-227 127% 222-400 80%
Norway % change 123-172 40% 85-224 163% 208-396 90%
Belgium % change 144-190 32% 144-197 37% 288-387 34%
Australia % change 136-172 26% 106-213 101% 242-385 59%
Canada 2013 % change 188-168 -11% # 167-233 40% 355-401 13%
New Zealand 2013 % change 138-152 10% 124-196 58% 262-348 33%
France % change 169-182 8% 135-154 14% 304-336 11%
Germany % change 104-135 30% 33-147 345% 137-282 106%
Italy % change 111-148 33% 103-133 29% 214-281 31%
Portugal % change 89-135 52% 52-121 133% 141-256 82%
Austria % change 78-134 72% 27-80 196% 106-214 102%
Greece % change 74-132 78% 38-52 37% 112-184 64%
Japan % change 44-71 61% 15-41 173% 59-112 nb90%
Table 2: Nervous Disease Deaths (NDD) & Alzheimer & Other Dementia Deaths (Alz) Total Age-Standardised-Death-Rates (ASDR) are Combined 
Neurological Mortality (CNM)per million 2000-2015 Ranked by Highest Rates.
Citation: Pritchard C, Silk A, Hansen L. Neurological Deaths in the 21st Century in 21 Western Countries: Demographics or Environmental 
Causes. Neurol Neurosurg Curr Res. 2021;2(1):19-26.
Page 22 of 26
Neurol Neurosurg Curr Res. (2021)
Volume 2 Issue 1 
except France AlzD rates rose by >50%. The average rise 
in NDD over the period was 52% and 110% for AlzD.
Every nation’s CNM increased by >30% except France up 
11% and Canada by 13%. 
Combined rates rose by more than 100% in Finland, 
Germany and the UK and by more than 75% in Denmark, 
Ireland, Japan, the Netherlands, Portugal and the USA.
Population and Neurological Deaths in the Over 
75’s
Table 3 presents WHO data for increases in population and 
CNM in the Over 75’s from which population to CNM Odds 
Ratios are calculated. The elderly population average rise 
was 33%, up 30% in 15 countries but CNM rises averaged 
120%, rose and more than doubled in twelve.
Apart from Canada, at 1:0.98, every nation’s population 
to CNM Odds Ratio was positive fifteen countries had 
ratios of more than 1:1.20. Whilst Odds Ratios more 
than doubled in the UK at 1:3.26, Norway 1:2.74, Austria 
1:2.54, Ireland 1:2.32, Denmark 1:2.07, with other 
notable rises in Finland 1:1.95, Germany and, Portugal 
1:78, Sweden 1:1.98 and the USA 1:1.83. 
Country and Widest 
Odds Ratio Rank Population Millions Ratio of Change Rate CNM Ratio of Change
Population: CNM 
Odds Ratio
UK 2000 2015 4.406 5.19  1.18 4005 15438  3.85  01:03.3




































































































































































Table 3: Over-75’s Population and Combined Neurological Mortality rates per million 2000-2015. Ratio of change Population to CNM then Odds 
Ratios. Ranked by highest Widest Population: CNM Odds Ratio.
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Mortality Numbers for Practice Implications 
To provide an indication of possible implications for 
services, actual numbers of deaths are reported. Table 4 
gives the increases in millions of populations and rises in 
numbers of CNM and the percentage of change. 
In respect to the 55-74-year-olds, except for Belgium, 
Canada and France, every countries CNM rose greater 
than any population rises. Whilst France was the major 
outlier, having a 4% fall in their numbers of deaths as 
against a 31% rise in the numbers of population. Overall 
population rises for the 55-74years averaged 29% over 
the period but average neurological deaths rise was 67%. 
Four countries had 100% increases namely the 
Netherlands 133%, USA 120%, Australia 108% and 
Finland 100%, whilst elven had increases of more 
than 50%. In twelve countries 55-75 population to 
neurological deaths were greater than 1:1.30.
In regard to the numbers of all neurological deaths 
seventeen countries rose by more than 100%, more 
than doubling in Norway 375%, the UK 321%, Japan 
299%, Finland 239%, Austria 236%, Germany 225% and 
Ireland 213%. Average rises in total population were 9% 
as against 175% rise in all neurological deaths over the 
period. In fourteen countries population to CMN numbers 
produced odds ratio of more than 1:2.00 over the period.
The widest total population to CMN odds ratios were in 
Norway at 1:4.09 who were tenth highest, whilst Japan, 
with the lowest rates had the second biggest rise over the 
period with an odds ratio of 1:4.03.
Three countries in particular merit further comment. 
The outlier country France, neurological deaths of people 
aged 55-74 deaths fell from 6,236 down to 5,997, an odds 
ratio of 1:0.73. Whereas their total neurological deaths 
went from 40,594 to 71,543, yielding an odds ratio of 
1:61. 
The UK, who were second highest, their 55-74-Year-
olds deaths rose from 4,650 to 9,019, an odds ratio of 
1:1.55 and total deaths rose from 24,601 to a remarkable 
103,550, producing an odds ratio of 1:3.86 over the 
period. 
Country 55-74, CNM 





Norway Population 371-616 0.757-1.088 1.66 1.44 1.15 1096-5203 4.470-5.189 4.75 1.16 4.09
Japan Population 4438-8099 29.392-33.471 1.82 1.14 1.6 14023-56027 125.612-125.319 3.99 0.99 4.03
UK Population 4650-9019 11.065-13.792 1.94 1.25 1.55  24601-103550 59.704-65.110 4.21 1.09 3.86
Germany Population 5790-9332 18.424-19.491 1.61 1.06 1.52 22543-73310 82.188-81.687 3.25 0.99 3.28
Austria Population 369-702 1.571-1.901 1.9 1.21 1.57 1519-5107 8.011-8.629 3.36 1.08 3.11
Finland Population 692-1385 0.991-1.377 2 1.39 1.45 5063-17155 5.176-5.482 3.23 1.06 3.1
Ireland Population 262-445 0.565-0.616 1.74 1.09 1.6 1080-3384 3.789-3.979 3.13 1.05 2.98
Portugal Population 779-1037 2.084-2.409 1.33 1.16 1.15 2842-7775 10.290-10.401 2.74 1.01 2.71
Netherlands Population 1026-2389 2.799-3.813 2,33 1.36 1.71 8279-21931 15.925-16.939 2.65 1.06 2.5
Denmark Population 465-798 1.023-1.325 1.72 1.30 1.32 2460-5925 5.337-5.678 2.41 1.06 2.27
Australia Population 1155-2407 3.072-4.749 2.08 1.55 1.34 7846-21594 19.153-23.781 2.75 1.24 2.22
USA population 21818-48047 42.666-67.380 2.2 1.58 1.39 174708-436438 281.421-319.929 2.5 1.14 2.19
Italy deaths Population 5693-6542 12.598-14.231 1.68 1.13 1.49 27554-61678 56.924-60.731 2.24 1.07 2.09
Greece Population 788-927 2.357-2.452 1.18 1.04 1.13 2092-4741 10.917-10.871 2.27 1.09 2.08
Spain Population 3892-5007 7.888-9.876 1.29 1.25 1.03 26679-62871 40.174-46.410 2.35 1.16 2.03
Sweden Population 743-1355 1.754-2.209 1.82 1.26 1.46 6159-13110 8.872-9.696 2.13 1.09 1.95
Belgium Population 1179-1363 2.020-2.462 1.16 1.22 0.95 6400-13054 10.251-11.266 2.04 1.10 1.85
Switzerland Population 601-972 1.373-1.814 1.62 1.32 1.23 4904-10225 7.209-8.320 2.09 1.15 1.82
N. Zealand Population 240-414 0.588-0.872 1.73 1.48 1.17 1689-3199 3.887-4.442 1.89 1.14 1.66
France Population 6236-5997 10.628-13.956 0.96 1.31 0.73 40594-71543 58.898-64.129 1.76 1.09 1.61
Canada Population 2649-3652 0.496-0.761 1.38 1.53 0.9 19293-35091 30.791-35.255 1.82 1.14 1.6
Table 4: Numbers-Both Sexes 55-74 and Total Combined Neurological Mortality (CNM) 2000-15. % Population (in millions). Percentage Change 
for Population and CMN. Ranked by Biggest Total Pop:CMN Odds Ratio
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The third highest country was the USA whose 55-74 
numbers of deaths went from 21,818 to 48,047, giving an 
odds ratio of 1:1.39. American total neurological deaths 
rising from 174,708 to 436,438 producing an odds ratio 
of 1:2.19 in just sixteen years. 
DISCUSSION 
Limitations
The limits in international comparative studies are due 
to how reliable are the data and the effect of the different 
configurations of each nation’s health-care system upon 
their mortality outcomes. However, the WHO database 
is the most consistent and reliable available and has 
annually reported data from 1968 and online from 1979 
onwards [27]. Moreover, by using each nation’s baseline 
and index year’s statistics as a control provides a degree 
of internal reliability, especially over such a short period 
of time. The main limit is that this study cannot explain 
the changes between the countries and especially the 
55-74 outcomes of the outlier countries Canada, France 
and, to a lesser extent, Belgium. One explanation may 
be that their people either developed their neurological 
condition later or survived into an older age-band, as 
eventually Belgium and France had substantial increases 
in their total neurological deaths than rises in population. 
Nonetheless, the study provides a baseline for future 
research to explore the any subsequent acceleration of 
neurological mortality.
The null hypothesis is rejected as the majority of WDC 
substantially increased its neurological mortality for 
people aged 55-74, indicating that some neurological 
diseases are starting earlier, with elven nations having 
substantial increases in `premature deaths of the 
55-74-year-old. Moreover, total mortality ASDR more 
than doubled in Austria, Finland, Germany and the UK, 
whilst fifteen nations combined rates rose by more than 
30% over the century 2000-2015. 
The speed of these changes poses a serious challenge to 
the general Gompertzian explanation [18,19], especially 
when considering the rises in early-onset-dementia, 
often occurring in people in their forties and fifties 
[21-26]. This is not to gainsay that there will be no 
Gompertzian elements as well as genetic and epigenetic 
factors contributing to the results. Indeed, we recall the 
first Professor of Genetics at Oxford in 1970, Sir Walter 
Bodmer’s famous adage “genetics loads the gun but the 
environment pulls the trigger” [28]. This in part explains 
why one particular environmental exposure, depending 
upon the under-lying genetic predisposition, appears to 
lead to different diseases, exemplified by the association 
of electromagnetism with the development of both 
cancer and neurological diseases [26,29-32]. The idea 
that these neurological increases are due to improved 
diagnosis and demographics [9]. [18,19] may well have a 
role to play but unlikely to be at such an accelerating pace 
in just sixteen years. The more likely explanation is that 
environmental and occupational factors impact upon 
under-lying genetic factors, creating oxidative stress that 
contributes to neuro-degeneration [3,4,10,11,13-17,29-
32]. One strong indicator of the influence of multiple-
interactive environmental factors is Finland, with its 
known genetic weighting for neurological disease which 
nevertheless doubled its rate in such a short time, whilst 
the USA who in 1989 were 15th highest of the twenty-one 
developed countries but in the space of twenty-five years 
rose to become the second highest in the Western world 
3. Such a marked change surely suggests environmental 
influence and can no longer be ignored.
A practical indication of accelerating neurological 
morbidity in Britain is the development of two new 
charities, ‘Young Dementia UK’ and ‘The Young 
Person’s section’ of ‘The Parkinson’s Disease Society’, 
suggesting both community and hospital services may 
be overwhelmed. Exemplified in the numbers of total 
neurological deaths, rising from under 30,000 in the UK 
to more than 100,000 and in America from 174,000 to 
more than 436,000.
Our concern is that there may be a parallel evolving, 
similar to what occurred with asbestosis, which often 
took twenty years to develop serious symptom from 
initial exposure. At the moment, the impact of the 
asbestos crisis is still being seen in major increases in 
mesothelioma cases going through the age-bands who 
were exposed earlier in the 20th century [33-35]. But 
more importantly, following Governmental preventative 
measures the incidence of mesothelioma began to decline 
[36]. Therefore, it seems self-evident that with the 
accelerating numbers of neurological patients there will 
be a need for enhanced services as well as prevention. 
It is feared that any necessary response could be 
hampered by the false assumption that increased 
neurological disease is largely due to demography 
rather than dis-proportionately more people developing 
neurological disease and at an earlier age. There is 
not only a need to determine what is causing these 
changes over such a short time span, but also a need 
for urgent action to prevent, treat and upgrade services 
accordingly. 
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Every major unsolved problem in science is usually 
nonlinear. This means that any discipline laboring in its 
own silo of science is very unlikely to find answers to 
problems which by their very nature-our human nature-
cross several disciplines. Consilience in research now 
is vital. The laws of physics and the laws of unintended 
consequences demand that we address the complex 
non-linear multifactorial problems which appear to 
be increasing exponentially. Whatever the interactive 
multiplicity of factors that had led to this acceleration, 
in view of the speed of change it must be predominately 
environmental reflecting the profound changes that have 
occurred in the last thirty years ranging from the possible 
inter-action of petro-chemical, endocrine chemicals, food 
additives, increased air, food and water pollution and the 
new digital world. That were new levels of background 
low exposure electro-magnetism water, then many of us 
would be living in a faint mist [26].
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